Introduction
GSK plc (LSE:GSK) is connected to abacavir, a long-established HIV medicine, through its majority interest in ViiV Healthcare, a specialist company focused on human immunodeficiency virus (HIV). Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI) used as part of combination antiretroviral therapy, and it appears in several ViiV medicines, including single-agent and fixed-dose combination products.
This article explains what abacavir is, how GSK is connected to it via ViiV Healthcare, and why that structure matters. It also sets out important safety context — in particular the need for HLA-B*5701 genetic testing before use — using reliable approved sources, and it distinguishes clinical facts from commercial analysis. It does not provide medical or financial advice, and it does not suggest abacavir is suitable for every patient.
What is the medicine?
Abacavir is an antiretroviral medicine belonging to the nucleoside reverse transcriptase inhibitor (NRTI) class. It is used in combination with other antiretroviral medicines to treat HIV infection; it is not used alone. In the MHRA index the substance appears in several forms, including abacavir, abacavir hydrochloride and abacavir sulfate, reflecting its use across different products.
Abacavir features in single-agent products such as Ziagen and in fixed-dose combinations such as Kivexa (with lamivudine), Trizivir (with lamivudine and zidovudine) and Triumeq (with dolutegravir and lamivudine). These combinations aim to simplify treatment by reducing the number of tablets a person takes.
Which UK-listed company is connected to it?
The abacavir-containing medicines are part of the portfolio of ViiV Healthcare, a specialist HIV company. GSK plc, which is listed on the London Stock Exchange under the ticker GSK, is the majority shareholder in ViiV Healthcare.
This is an important structural distinction. GSK’s connection to abacavir is through its controlling interest in ViiV, rather than abacavir being a product of GSK’s general medicines division. ViiV was established as a dedicated HIV business, and its ownership has historically included other pharmaceutical companies as minority shareholders.
Publicly reported figures have indicated that GSK holds a majority stake in ViiV of around 78 per cent, with the remaining minority interest held by other shareholders. That structure changed during 2026, when Pfizer agreed to exit its holding and Shionogi increased its interest, while GSK retained majority control. Because the exact percentages have moved over time, investors should confirm the current position from GSK’s own disclosures.
What does the MHRA substance listing establish?
MHRA index entries for abacavir, abacavir hydrochloride and abacavir sulfate confirm only that regulatory or product files exist under those active substances. Such listings do not, on their own, establish ownership, commercial rights, revenue, patent status, market exclusivity or clinical superiority.
They also do not mean the named company owns every product containing that substance; abacavir is available from multiple manufacturers, including generic suppliers, following patent expiry. This article’s statements about ViiV and GSK are based on company disclosures, not on the substance index alone.
What is the product approved to treat?
Abacavir-containing medicines are indicated, according to their approved product information, for the treatment of HIV infection in combination with other antiretroviral agents. The specific approved populations, ages and combinations depend on the individual product.
Because abacavir is used as part of combination therapy, it is one component of a broader regimen designed to suppress the virus. It does not cure HIV; approved antiretroviral therapy aims to control the infection. Readers should consult the current Summary of Product Characteristics for each product for precise indications and conditions of use.
Modern HIV care aims to reduce the amount of virus in the blood to very low levels, which supports the health of the person living with HIV and, according to public-health guidance, has important implications for onward transmission. Abacavir-containing regimens are one of several approved ways to build an effective combination, chosen according to individual clinical factors.
How does the medicine work?
HIV replicates by converting its genetic material using an enzyme called reverse transcriptase. NRTIs such as abacavir act as faulty building blocks that interfere with this process, helping to reduce the amount of virus in the body when used within an effective combination regimen.
Effective HIV treatment typically combines agents from more than one class to suppress viral replication and reduce the risk of resistance. Abacavir’s role is as one such backbone component. Individual regimen choice is made by specialist clinicians based on the patient’s circumstances, testing and history.
What are the key clinical and regulatory safety points?
A critical safety point is that abacavir can cause a serious hypersensitivity reaction in a minority of people, and this risk is strongly associated with a genetic marker called HLA-B*5701. Approved guidance and product information state that patients should be tested for HLA-B*5701 before starting abacavir, and abacavir should not be used in those who test positive.
This testing requirement, introduced as a risk-mitigation measure and supported by clinical evidence, has substantially reduced hypersensitivity reactions in practice. It is a clear example of why abacavir is not appropriate for every patient, and why prescribing decisions belong to qualified healthcare professionals following current approved sources.
Approved product information for abacavir also includes other warnings that clinicians take into account, and over the years there has been scientific discussion about possible cardiovascular considerations in some analyses. Such questions are matters for specialist assessment and regulatory review rather than general commentary, and this article does not draw conclusions about them; the settled, clearly established safety measure remains HLA-B*5701 testing before use.
How important is the product to the company’s portfolio?
Abacavir is a mature medicine within ViiV Healthcare’s portfolio. ViiV’s more recent commercial emphasis has shifted toward integrase inhibitor-based regimens and long-acting options, though abacavir-containing combinations such as Triumeq have been significant products historically.
For GSK, HIV is a meaningful part of group performance through its majority interest in ViiV, but abacavir specifically is one component of that business rather than the whole. GSK reports HIV performance within its results; where product-level figures for abacavir are not separately disclosed, this article does not estimate them.
ViiV’s strategy in recent years has centred on two-drug regimens and long-acting therapies that reduce dosing frequency, which has drawn commercial attention away from older triple-therapy combinations. Abacavir-containing products remain part of the mix, but the growth narrative for ViiV, and therefore for GSK’s HIV exposure, has increasingly rested on newer assets rather than on abacavir alone.
What is the size and nature of the addressable market?
HIV treatment is a large, long-term global market, because antiretroviral therapy is generally taken for life and demand is driven by the number of people living with HIV and receiving care. In higher-income markets such as the UK, treatment is guided by specialist bodies and national frameworks.
Within that market, the abacavir segment is shaped by prescribing preferences, the availability of newer regimens, and generic competition. As older combinations face generic alternatives, branded abacavir-containing products can see pricing and volume pressure, even as the overall HIV market remains substantial.
The UK, like many health systems, also emphasises value for money in HIV care, and the availability of low-cost generic antiretrovirals has changed prescribing economics. This can benefit health systems and patients through lower costs, while compressing the branded revenue available from mature molecules such as abacavir.
What competing treatments are available?
The HIV treatment landscape includes multiple drug classes and many combination regimens. Alternative backbones include tenofovir-based combinations, and integrase inhibitor-based regimens have become widely used. Long-acting injectable options have also emerged, changing how some patients are treated.
ViiV itself markets several non-abacavir regimens, so competition exists both from other companies and from newer ViiV products. Generic versions of abacavir and some abacavir-containing combinations further intensify competition. Treatment selection is individualised and determined by clinicians.
What could support future demand?
Factors that could support continued use of abacavir-containing regimens, subject to clinical judgement, include established long-term experience, suitability for certain patients, and the role of fixed-dose combinations in simplifying treatment. Availability of lower-cost generic versions may also sustain use in some settings.
However, demand for branded abacavir products may be tempered by the shift toward newer regimens and long-acting options. Any future contribution to GSK will depend on prescribing trends, competition, pricing and the broader evolution of HIV care, none of which is guaranteed.
What are the principal clinical, regulatory and commercial risks?
Clinically, the hypersensitivity risk associated with HLA-B*5701 is the most prominent consideration, alongside other warnings and potential adverse effects described in approved labelling. Regulatory and safety monitoring of antiretrovirals is ongoing, as with all medicines.
Commercially, key risks include generic erosion of older combinations, competition from newer regimens, pricing pressure, and the indirect nature of GSK’s exposure through ViiV. Changes in ViiV’s ownership structure over time can also affect how the business is consolidated and reported by GSK.
Patent expiries are a particular consideration for a mature molecule like abacavir, since generic availability tends to reduce both price and branded volume. For investors, the relevant question is less about abacavir in isolation and more about how ViiV as a whole sustains growth as its portfolio matures and newer regimens take a larger role.
What should investors monitor next?
Investors may wish to monitor GSK’s disclosures on HIV performance and on ViiV Healthcare, including any changes to ViiV’s ownership structure and how they affect reporting. They may also track the balance between older regimens such as abacavir combinations and newer long-acting options.
Additional data points include generic-competition timelines for key products, prescribing-guideline updates, and GSK’s broader pipeline in infectious disease. These are verifiable against GSK and ViiV disclosures and specialist HIV sources.
Because ViiV’s ownership changed during 2026, the way GSK accounts for and describes its HIV interest is itself worth following, including any commentary on minority interests and how they affect attributable earnings. These are technical but material points for anyone assessing GSK’s exposure to the HIV franchise.
Balanced conclusion
Abacavir is a long-standing HIV backbone medicine within ViiV Healthcare, the specialist company in which GSK plc (LSE:GSK) is the majority shareholder. For investors, the key nuance is that GSK’s exposure to abacavir is indirect and sits within a broader HIV business that has increasingly emphasised newer regimens. The essential safety point — HLA-B*5701 testing before use — underlines that abacavir is not suitable for everyone.
On balance, abacavir remains clinically relevant but commercially mature, and its future contribution depends on competition, prescribing trends and market dynamics rather than on any active-substance listing. The medicine’s enduring place in HIV care reflects long clinical experience, but its investment relevance to GSK is best judged at the level of ViiV Healthcare and the wider HIV market rather than through any single molecule. Readers considering action based on this information should consult the primary sources cited and, where appropriate, professional advice.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...